Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gardasil Sails Through Committee; Discussions Center On Labeling Language

Executive Summary

Labeling for Merck's Gardasil should emphasize that the link between vaccine-related human papilloma virus types and cervical cancer has not been clearly shown, members of FDA's Vaccines & Related Biological Products Advisory Committee said in recommending approval May 18

You may also be interested in...



Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?

A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.

Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?

A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.

Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?

Nov. 17 session is product's third before an FDA advisory committee, but review by CDC's immunization practices panel may be key for utilization and reimbursement.

Related Content

UsernamePublicRestriction

Register

PS047195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel